Scale access to FDA-cleared mental health treatments

SleepioRx and DaylightRx provide guideline-recommended treatment for members and tangible cost savings for health plans.

Request Demo

FDA-Cleared

500K+ Patients

Treated & supported

App Store Rating

Vetted & Secure

HIPAA compliant &
HITRUST certified

Reimbursable

by Insurance

Instantly accessible, cost-effective, guideline-recommended care

Instant access to first-line care

Help members get immediate access to CBT, a gold-standard treatment for insomnia and anxiety^1,2

Proven to deliver tangible cost savings

One-time expense for digital treatment that addresses the root causes of mental health conditions with lasting results

Trusted by providers & clinical organizations

Help your provider network manage demand and costs with reimbursable treatments under new billing codes

Explore Treatments

Read FAQs

DIGITAL TREATMENTS REIMBURSED THROUGH INSURANCE

Sleepio RX

76% of insomnia patients achieve clinical improvement with no serious side effects³

Daylight RX

71% of anxiety patients achieve clinical improvement with no serious side effects⁴

Clinical results at a fraction of the cost

We offer a one-time payment for a 90-day course of treatment, delivering results at a fraction of the average provider-delivered cost.

40%

Decrease in inpatient costs⁵

20%

Decrease in outpatient costs⁵

37%

Decrease in Rx claims costs⁶

Request Demo

BY THE NUMBERS

Evidence for SleepioRx and DaylightRx

Read the Research

50+

Peer-reviewed evidence publications

Completed randomized controlled trials

References in clinical guidelines like the American College of Physicians¹

FAQs

What are SleepioRx and DaylightRx?

SleepioRx¹ and DaylightRx² are FDA-cleared digital treatments for insomnia disorder and generalized anxiety disorder, respectively, delivering guideline-recommended cognitive behavioral therapy (CBT) through video and audio lessons in mobile apps. Designed by sleep and anxiety experts, the treatments help patients understand unhealthy patterns and address the thoughts and behaviors that sustain insomnia and anxiety. CBT techniques delivered in an engaging and interactive format help patients overcome insomnia and anxiety, quickly.
‍

1. SleepioRx is a digital therapeutic intended for the treatment of chronic insomnia/insomnia disorder as an adjunct to usual care in patients aged 18 and older. SleepioRx is a prescription device delivering Cognitive Behavioral Therapy for Insomnia (CBT-I) and can be made available on the order of a licensed healthcare provider. Patients should read the instructions for use for full information.
2. DaylightRx is a prescription device delivering Cognitive Behavioral Therapy and can be made available on the order of a licensed healthcare provider. DaylightRx is a digital therapeutic intended to treat generalized anxiety disorder (GAD) by improving a patient's GAD symptoms as an adjunct to usual care in patients aged 22 years and older. Patients should read the instructions for use for full information.

What evidence is there showing that SleepioRx and DaylightRx work?

SleepioRx has been tested to the highest standards of clinical evidence in 26 clinical trials, including 18 randomized controlled trials (RCTs). Across these studies, SleepioRx outperforms rigorous controls, including sham-placebo, usual care, and sleep hygiene, with up to 76% of SleepioRx patients achieving healthy sleep by post-treatment.^1-4 Data suggest that patients continue to experience benefits 1 year or longer after starting SleepioRx.^5,6

DaylightRx has been evaluated across 2 rigorous RCTs and one single-arm trial. DaylightRx has demonstrated superiority compared to an active psychoeducation control, with 71% of DaylightRx participants achieving GAD remission based on clinical interview compared to 35% of control participants,⁷ with consistent results observed on self-reported measures.⁸ Results from these trials demonstrate that benefits conferred by DaylightRx are maintained until at least 6 months.⁷
‍

1. Espie et al. (2012). SLEEP, 35(6), 769-781.
2. Tamm et al. (2025). JAMA Network Open, 8(2), e2461502-e2461502.
3. Tarnai et al. (2025). Aging and Mental Health, 1-7
4. Internal RCT data, August 2023.
5. Luik et al. (2020). Journal of Sleep Research, 29(4), e13018.
6. Cheng et al. (2021). SLEEP, 44(4), zsaa258.
7. Internal RCT data, September 2023.
8. Carl et al. (2020). Depression & Anxiety, 37(12), 1168-1178.

How do I order SleepioRx and DaylightRx for my patients?

You can place an order and start distributing SleepioRx or DaylightRx to your qualifying patients in three simple steps:
‍
Step 1: Big Health provides providers with a website for ordering, along with unique access codes. Print and digital referral materials are also available if needed.
Step 2: The provider identifies qualifying patients, explains SleepioRx or DaylightRx, and enters a unique access code and the patient's phone number on the website.
Step 3: The patient receives a text message with instructions for accessing, downloading and signing up for SleepioRx or DaylightRx.

Which insurers cover SleepioRx and DaylightRx?

The Centers for Medicare & Medicaid Services (CMS) has finalized three new Digital Mental Health Treatment (DMHT) codes in the Calendar Year (CY) 2025 Medicare Physician Fee Schedule as of January 1, 2025, allowing providers a reimbursement opportunity for prescribing DMHTs like SleepioRx and DaylightRx to Medicare patients. While we are actively engaging other insurance carriers to expand coverage, these DMHT codes are not a guarantee of reimbursement.

What types of providers can authorize use of SleepioRx and DaylightRx and bill for reimbursement?

Licensed providers who are able to offer behavioral therapy or behavioral health care within their scope of practice can order SleepioRx or DaylightRx and bill for the codes.This includes the following practitioners:
‍
- Psychiatrists & other doctors (MDs, DOs)
- Clinical psychologists
- Clinical social workers (LCSWs, LICSWs)
- Advanced practice nurses/Nurse practitioners (NPs)
- Physician assistants (PAs)
- Marriage & family therapists (LMFTs)
- Mental health counselors

Check commercial payer policies for restrictions. The billing practitioner or a colleague should oversee patient care and adjust treatment as needed. They may also supervise non-qualifying practitioners in providing these services.

Ready to cover first-line treatments for behavioral health conditions?

Qaseem A, Kansagara D, Forciea MA, Cooke M, Denberg TD; Clinical Guidelines Committee of the American College of Physicians. Management of Chronic Insomnia Disorder in Adults: A Clinical Practice Guideline From the American College of Physicians. Ann Intern Med. 2016 Jul 19;165(2):125-33. doi: 10.7326/M15-2175. Epub 2016 May 3. PMID: 27136449.
DeGeorge KC, Grover M, Streeter GS. Generalized Anxiety Disorder and Panic Disorder in Adults. Am Fam Physician. 2022 Aug;106(2):157-164. PMID: 35977134.
Changes up to these levels have been demonstrated across studies, including:
- Espie, C. A., Kyle, S. D., Williams, C., Ong, J. C., Douglas, N. J., Hames, P., & Brown, J. S. (2012). A randomized, placebo-controlled trial of online cognitive behavioral therapy for chronic insomnia disorder delivered via an automated media-rich web application. SLEEP, 35(6), 769–781.
- Tarnai, Kathryn A; Miller, Christopher B; Magill, Nicholas; Emsley, Richard; Robinson, Will; Kyle, Simon D; McGrath, Emer R; Espie, Colin A; Henry, Alasdair L. (2025). Efficacy of digital cognitive behavioral therapy for treating insomnia in adults aged 65 and older: a secondary analysis using individual participant data from three randomized controlled trials. Aging and Mental Health. pp. 1-7. ISSN 1360-7863.
Carl, J. R., Miller, C. B., Henry, A. L., Davis, M. L., Stott, R., Smits, J. A. J., Emsley, R., Gu, J., Shin, O., Otto, M. W., Craske, M. G., Saunders, K. E. A., Goodwin, G. M., & Espie, C. A. (2020). Efficacy of digital cognitive behavioral therapy for moderate-to-severe symptoms of generalized anxiety disorder: A randomized controlled trial. Depression and anxiety, 37(12), 1168–1178. https://doi.org/10.1002/da.23079
Internal Data, compared to network averages, Nov 2023.
Internal Data, observed in independently conducted HEOR study of digital program in an employer population, May 2020.

SleepioRx and DaylightRx are prescription digital therapeutics, available by order of a licensed healthcare provider, for use alongside usual care. SleepioRx treats chronic insomnia in adults 18+, and DaylightRx treats generalized anxiety disorder (GAD) in adults 22+. Patients should read the instructions for use for full information. These statements are in no way intended to imply or suggest any claims regarding SleepioRx and DaylightRx beyond its FDA cleared indications and should in no way be considered a guarantee of coverage or reimbursement for any product or service. These statements are intended to provide information to practitioners, they do not seek to maximize payment, and should not be mistaken for official payer guidance.

DOC-3515 Effective June 2025